MedAdvisor Ltd (ASX: MDR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

MedAdvisor Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $165.39 million
P/E Ratio 315.38
Dividend Yield 0.00%
Shares Outstanding 551.31 million
Earnings per share -0.018
Dividend per share N/A
Year To Date Return 62.79%
Earnings Yield 0.32%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • MedAdvisor Ltd (ASX: MDR)
    Latest News

    a woman
    Share Market News

    Here's why this ASX medical tech share surged 14% today

    The Medadvisor Ltd (ASX:MDR) share price surged 13.92% higher today after the company released its half-year FY20 results.

    Read more »

    a woman
    Share Market News

    Why these 3 ASX shares slumped lower today

    With the S&P/ASX 200 Index (INDEXASX: XJO) trading higher today, let's take a look at why these 3 ASX shares fared…

    Read more »

    a woman
    Share Market News

    3 ASX medical tech shares surging higher today

    Here are 3 ASX shares in the fast-growing medical tech sector that have seen gains of around 5% so far…

    Read more »

    a woman
    Share Gainers

    Medadvisor share price rockets 28% higher on U.S. update

    The Medadvisor Ltd (ASX:MDR) share price was one of the best performers on the Australian share market on Thursday...

    Read more »

    a woman
    Share Market News

    SaaS player MedAdvisor Ltd raises $17 million for growth push

    MedAdvisor is a little-known tech and healthcare small cap.

    Read more »

    a woman
    ⏸️ Investing

    Why the MedAdvisor Ltd (ASX:MDR) share price is up 20% today

    MedAdvisor Ltd (ASX:MDR) jumps 20% to 4.8 cents in morning trade following the announcement that it has signed a Co-Marketing and Licence…

    Read more »

    a woman
    ⏸️ Investing

    These tech shares are flying

    These three tech shares are making investors happy…

    Read more »

    a woman
    ⏸️ Investing

    3 Exciting Med-Tech Stocks For Asthma: Are They Any Good?

    Technology to treat chronic disease can be very profitable, but that doesn't mean every company that aims to treat chronic…

    Read more »

    MDR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About MedAdvisor Ltd

    MedAdvisor Ltd is engaged in the development and deployment of the MedAdvisor medication and adherence platform. The MedAdvisor platform is focused on improving health outcomes by connecting health professionals with their patients using mobile and web technologies. It has three reporting segments: ANZ Operations, U.S. Operations and UK Operations. The company derives majority of its revenues from U.S. Operations.

    MDR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Nov 2024 $0.30 $0.01 3.45% 442,710 $0.29 $0.30 $0.29
    20 Nov 2024 $0.29 $0.02 7.27% 3,240,828 $0.27 $0.29 $0.27
    19 Nov 2024 $0.28 $-0.02 -6.78% 922,064 $0.29 $0.29 $0.27
    18 Nov 2024 $0.30 $-0.01 -3.33% 685,867 $0.32 $0.32 $0.29
    15 Nov 2024 $0.30 $0.01 3.45% 889,693 $0.29 $0.30 $0.28
    14 Nov 2024 $0.29 $0.04 16.00% 1,109,675 $0.26 $0.31 $0.25
    13 Nov 2024 $0.25 $-0.01 -3.92% 664,189 $0.26 $0.26 $0.25
    12 Nov 2024 $0.26 $-0.01 -3.77% 424,457 $0.27 $0.27 $0.26
    11 Nov 2024 $0.27 $0.00 0.00% 526,989 $0.27 $0.27 $0.26
    08 Nov 2024 $0.27 $0.02 8.00% 1,150,159 $0.26 $0.29 $0.26
    07 Nov 2024 $0.25 $0.00 0.00% 1,369,897 $0.25 $0.26 $0.25
    06 Nov 2024 $0.25 $0.01 4.17% 61,020 $0.24 $0.25 $0.24
    05 Nov 2024 $0.24 $-0.01 -4.00% 243,266 $0.26 $0.26 $0.24
    04 Nov 2024 $0.25 $0.00 0.00% 1,247,105 $0.26 $0.27 $0.25
    01 Nov 2024 $0.25 $0.02 8.51% 1,327,145 $0.23 $0.26 $0.23
    31 Oct 2024 $0.24 $-0.12 -34.29% 19,824,207 $0.32 $0.32 $0.19
    30 Oct 2024 $0.35 $0.02 5.97% 22,208 $0.34 $0.35 $0.34
    29 Oct 2024 $0.34 $-0.01 -2.94% 533,852 $0.34 $0.37 $0.34
    28 Oct 2024 $0.34 $0.00 0.00% 127,499 $0.35 $0.35 $0.33
    25 Oct 2024 $0.35 $0.00 0.00% 208,659 $0.35 $0.35 $0.34
    24 Oct 2024 $0.34 $0.00 0.00% 730,916 $0.35 $0.36 $0.34
    23 Oct 2024 $0.35 $-0.01 -2.82% 291,375 $0.36 $0.36 $0.35
    22 Oct 2024 $0.36 $-0.01 -2.74% 851,523 $0.37 $0.37 $0.35

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Nov 2023 Catherine (Kate) Hill Issued 1,000,000 $230,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Catherine (Kate) Jane Hill Non-Executive Director May 2023
    Ms Hill is auditor and business advisor with over 30 years of experience of working with privately owned and ASX-listed companies across a range of business issues. A former senior partner and first female board member of top 4 accounting firm Deloitte, she has in recent years turned her focus, her energies, and experience into Non-Executive Director roles. She is a director of small to mid-cap companies listed on ASX and other global exchanges, with a track record in change involving new business models, new markets, and new technologies. She is chair of Risk Committee and member of People Committee.
    Mr Jim Xenos Non-Executive Director Nov 2015
    Mr Xenos is currently the Chief Executive Officer of NostraData Pty Limited, which he co-founded in 2010. Prior to co-founding NostraData, Jim held several Associate Director positions with GlaxoSmithKline PLC. Jim was also the Head of Retail at Sigma Healthcare Limited for Herron Pharmaceuticals. She is Chair of people committee.
    Ms Linda Jenkinson Non-Executive ChairmanNon-Executive Director Feb 2022
    Ms Hill is auditor and business advisor with over 30 years' experience of working with privately owned and ASX-listed companies across a range of business issues. A former senior partner and first female board member of top 4 accounting firm Deloitte, she has in recent years turned her focus, her energies, and experience into Non-Executive Director roles. She is aa director of small to mid-cap companies listed on ASX and other global exchanges, with a track record in change involving new business models, new markets, and new technologies. She is chair of Risk Committee and member of People Committee.
    Mr Lucas Merrow Non-Executive Director Aug 2021
    Mr Merrow co-founded and served as the Chief Executive Officer of Eliza Corporation-the leader in health engagement management and patient communications. Eliza Corporation was later acquired. Prior to the founding of Eliza Corporation, Lucas co-founded and served as the Chief Operating Officer of Adheris Health, a leading firm in prescription adherence and patient education programs in the United States. MedAdvisor acquired Adheris Health in November 2020. He is Member of People Committee.
    Mr Richard (Rick) Ratliff Chief Executive OfficerManaging Director Jul 2022
    Mr Ratliff spent over 30 years in the healthcare and pharmaceutical technology sector in key markets in which MedAdvisor Solutions operates. He has led the development of several large-scale technology-enabled healthcare businesses within global organizations such as IBM and Accenture as well as via start-up and early-stage businesses, including Healthvision, Surescripts, and ConnectiveRx. Rick also worked with the Australian federal government to develop and deliver My Health Record, the leading online EHR available to all Australian citizens. He is a member of People Committee.
    Mr Kevin Hutchinson Non-Executive Director Nov 2022
    Mr Hutchinson is an entrepreneur with 30 years of experience in the tech industry. He has built and grown companies that deliver innovative services by using disruptive technology. He also has seen great success in his ability to accelerate growth by hiring and developing teams that drive exceptional results. He has served in numerous C-level executive roles, including CEO and COO, as well as several non-executive board appointments. Kevin is CEO and Director of AXL Health and on the Board of Matrix Analytics dba eon Health. He is a member of Risk Committee.
    Ms Ancila Desai Chief Financial OfficerCompany Secretary Feb 2023
    -
    Mr Anshu Raghuvanshi Joint Company Secretary Mar 2023
    -
    Ancila Desai Chief Financial OfficerCompany Secretary
    -
    Anshu Raghuvanshi Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Guild Group Holdings Limited 94,905,130 17.21%
    HSBC Custody Nominees (Australia) Limited 84,152,463 15.26%
    Ebos Ph Pty Ltd 53,986,823 9.79%
    J P Morgan Nominees Australia Pty Limited 45,226,380 8.20%
    Cotiviti Inc 43,999,999 7.98%
    Citicorp Nominees Pty Limited 38,361,455 6.96%
    National Nominees Limited 14,892,708 2.70%
    UBS Nominees Pty Ltd 14,289,149 2.59%
    Bond Street Custodians Limited <Salter - D79836 A/C> 9,700,000 1.76%
    Kojent Pty Ltd <Kojent A/C> 6,846,956 1.24%
    Indcorp Consulting Group Pty Limited <Superannuation Fund A/C> 6,550,000 1.19%
    Romida Enterprises Pty Ltd <Romida Family A/C> 5,642,935 1.02%
    Gread Management Pty Limited <The A G & R R Family A/C> 5,344,283 0.97%
    Provare Pty Ltd <Provare Investment A/C> 3,743,419 0.68%
    Tagdime Pty Ltd <Ian M Davison P/L S/F A/C> 3,264,316 0.59%
    Dr Christopher Harold Benton 3,000,000 0.54%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 2,815,940 0.51%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 2,383,158 0.43%
    Dmx Capital Partners Limited 2,351,551 0.43%
    Wavey Industries Pty Ltd <Josh Swinnerton Family A/C> 2,300,000 0.44%

    Profile

    since

    Note